Michael Gonsalves MBBS, Presenter: Nothing to Disclose

Arjun Nair MBBS, Abstract Co-Author: Nothing to Disclose

Ioannis Vlahos MBBS, Abstract Co-Author: Research grant, Bayer AG Support, Bayer AG Research Consultant, Siemens AG

Myrna Cobos Barco Godoy MD, Abstract Co-Author: Research grant, Bayer AG

Sisa Grubnic MD, Abstract Co-Author: Nothing to Disclose

1) Review pathological pathways of pulmonary drug toxicity and the resultant radiological manifestations as seen in established drugs 2) Summarize the pharmacological classes and indications for new therapeutic agents 3) Illustrate the radiology of new pulmonary drug toxicities via established and new pathological mechanisms    

1) Table: mechanisms of pulmonary drug toxicity and common causative agents with MDCT HRCT examples 2) Summary of classes, names and clinical uses of new drugs 3) Demonstrate MDCT HRCT appearance of toxicity due to novel agents e.g. interferon, anti-TNF, GM-CSF, tyrosine kinase inhibitors, other anti-angiogenic, immunomodulatory and chemotherapeutic agents.  

1) Understand the commonly encountered histopathological sequelae of pulmonary drug toxicity and their associated radiological manifestations 2) Understand from a radiological perspective new drug classes, their trade names and patients in whom in to expect their usage 3) Understand the radiological patterns of pulmonary toxicity encountered with novel drug therapies, risk factors, interactions and clinical outcomes.

Gonsalves, M, Nair, A, Vlahos, I, Godoy, M, Grubnic, S, Pulmonary Drug Toxicity: Radiological Appearances and Pathological Mechanisms of Established and Novel Agents .  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/6017887.html